• No results found

Pituitary diseases: long-term clinical consequences Klaauw, A.A. van der

N/A
N/A
Protected

Academic year: 2021

Share "Pituitary diseases: long-term clinical consequences Klaauw, A.A. van der"

Copied!
7
0
0

Bezig met laden.... (Bekijk nu de volledige tekst)

Hele tekst

(1)

Pituitary diseases: long-term clinical consequences

Klaauw, A.A. van der

Citation

Klaauw, A. A. van der. (2008, December 18). Pituitary diseases: long-term clinical consequences. Retrieved from https://hdl.handle.net/1887/13398

Version: Corrected Publisher’s Version

License: Licence agreement concerning inclusion of doctoral thesis in the Institutional Repository of the University of Leiden Downloaded from: https://hdl.handle.net/1887/13398

Note: To cite this publication please use the final published version (if applicable).

(2)

Pituitary diseases

Long-term clinical consequences

Agatha BW.indd 1

Agatha BW.indd 1 10/29/08 3:18:17 PM10/29/08 3:18:17 PM

(3)

Omslag, lay-out en druk verzorgd door Optima Grafi sche Communicatie, Rotterdam.

Een deel van de studies beschreven in dit proefschrift werd uitgevoerd als AGIKO, met gedeeltelijke fi nanciele ondersteuning van ZonMW.

De druk van dit proefschrift werd gedeeltelijk fi nancieel ondersteund door ZonMW en het onderzoeksfonds van het Bronovo Ziekenhuis.

Agatha BW.indd 2

Agatha BW.indd 2 10/29/08 3:18:18 PM10/29/08 3:18:18 PM

(4)

Pituitary diseases: long-term clinical consequences

Proefschrift

ter verkrijging van

de graad van Doctor aan de Universiteit Leiden

op gezag van de Rector Magnifi cus prof.mr. P.F. van der Heijden, volgens besluit van het College voor Promoties

te verdedigen op donderdag 18 december 2008

klokke 11.15 uur

door

Agatha Apolonia van der Klaauw

geboren te Leiderdorp in 1980

Agatha BW.indd 3

Agatha BW.indd 3 10/29/08 3:18:18 PM10/29/08 3:18:18 PM

(5)

PROMOTIECOMMISSIE

Promotores: Prof. dr. J.A. Romijn Prof. dr. J.W.A. Smit

Copromotor: Dr. A.M. Pereira

Referent: Prof. dr. E. Fliers, Afdeling Endocrinologie en Metabolisme, AMC, Amsterdam.

Overige leden: Prof. dr. J.A. Bolk Prof. dr. H. Delemarre Dr. I.S. Farooqi Prof. dr. S. Papapoulos Prof. dr. J.M. Wit

Agatha BW.indd 4

Agatha BW.indd 4 10/29/08 3:18:22 PM10/29/08 3:18:22 PM

(6)

Contents

1. General introduction 7

Studies in patients with acromegaly

2. Uncontrolled acromegaly is associated with progressive mitral valvular regurgitation.

31

3. Increased aortic root diameters in patients with acromegaly. 43 4. Previous radiotherapy negatively infl uences quality of life during four years of

follow-up in patients cured from acromegaly.

57

5. Somatostatin analog treatment is associated with an increased sleep latency in patients with long-term biochemical remission of acromegaly.

71

6. GH defi ciency in patients irradiated for acromegaly: signifi cance of GH stimulatory tests in relation to the 24 h GH secretion.

85

7. Cardiac manifestations of growth hormone defi ciency after treatment for acromegaly: a comparison to patients with biochemical remission and controls.

99

8. Limited eff ects of growth hormone replacement in patients with growth hormone defi ciency during long-term cure of acromegaly.

115

9. Postoperative radiotherapy for acromegaly delays the circadian phase of melatonin secretion.

129

Studies in patients with growth hormone defi ciency

10. Recombinant human growth hormone replacement increases CD34+ cells and improves endothelial function in adults with growth hormone defi ciency.

141

11. Sustained eff ects of recombinant GH replacement after 7 years of treatment in adults with GH defi ciency.

155

12. The prevalence of the metabolic syndrome is increased in patients with GH defi ciency, irrespective of long-term substitution with recombinant human GH.

169

13. Administration route-dependent eff ects of estrogens on IGF-I levels during fi xed GH replacement in women with hypopituitarism.

187

14. Infl uence of the d3-growth hormone receptor isoform on short-term and long-term treatment response to growth hormone replacement in growth hormone defi cient adults.

203

Agatha BW.indd 5

Agatha BW.indd 5 10/29/08 3:18:22 PM10/29/08 3:18:22 PM

(7)

6

Contents

Studies on quality of life in patients with pituitary diseases

15. Disease specifi c impairments in quality of life during long-term follow-up of patients with diff erent pituitary adenomas.

219

16. Increased daytime somnolence despite normal sleep patterns in patients treated for nonfunctioning pituitary macroadenoma.

241

17. Patients cured from craniopharyngioma or non-functioning pituitary macroadenoma suff er similarly from increased daytime somnolence despite normal sleep patterns compared to healthy controls.

257

18. General discussion and summary 271

19. Nederlandse samenvatting 301

Curriculum Vitae 315

List of publications 316

Agatha BW.indd 6

Agatha BW.indd 6 10/29/08 3:18:23 PM10/29/08 3:18:23 PM

Referenties

GERELATEERDE DOCUMENTEN

Since there could be residual cardiac manifestations of previous GH excess in patients in biochemical remission from acromegaly, we also compared the patients with GHD

In addition, a recent study compared the eff ects of 2 years of rhGH replacement on body composition, muscle strength, bone mass and metabolic param- eters between 10

Unfor- tunately, diurnal variations of pituitary hormones can not be used for assessment of the diurnal regulation by the SCN in patients previously treated for pituitary

The aim of this study was to assess vascular structure and function in relation to circulating CD34+ cells in adults with GHD before and during 1 year of recombinant human

Short-term (up to 24 months) replacement therapy with rhGH decreases the plasma concentra- tions of LDL cholesterol, total cholesterol, as well as fat mass and diastolic blood

The metabolic syndrome was scored using the National Cholesterol Education Program-Adult Treatment Panel III (NCEP-ATP III) defi nition in 50 consecutive GHD patients (age 45 ±

In order to diff erentiate between the eff ects of serum estradiol concentrations per se and the route of estrogen administration on IGF-I levels in hypogonadal GH-defi cient

The increase in IGF-I levels was remarkably higher during short-term rhGH replacement in heterozygous patients bearing at least one allele of the d3GHR compared to patients